Table 4.
Changes in circulating steroid hormones
| Baseline [N = 27] | 1 month [N = 27] | 2 months [N = 22] | 3 months [N = 20] | 4 months [N = 8] | 5 months [N = 7] | 6 months [N = 6] | P for 3 monthsa | P for 6 monthsa | |
|---|---|---|---|---|---|---|---|---|---|
| Androstenedione (ng/dl) | 59.5 (46.8–78.2) [n = 24] | 35.0 (28.5–55.0) [n = 23] | 44.0 (41.0–63.0) [n = 21] | 46.0 (30.5–55.5) [n = 19] | 36.0 (30.5–52.0) [n = 7] | 23.0 (21.0–29.0) [n = 7] | 36.0 (31.5–42.0) [n = 4] | <0.01 [n = 17] |
0.29 [n = 3] |
| Oestrone sulfate (ng/dl) | 40.0 (40.0– 70.8) [n = 26] | 40.0 (40.0– 70.0) [n = 26] | 40.0 (40.0– 81.0) [n = 21] | 40.0 (40.0– 53.5) [n = 20 | 40.0 (40.0–158.0) [n = 7] | 65.0 (40.0–152.5) [n = 7] | 61.0 (57.0–113.8) [n = 6] | 0.53 [n = 20] | 0.53 [n = 6] |
| DHEA (ng/dl) | 118.5 (77.5–194.0) [n = 24] | 84.5 (56.0–137.2) [n = 24] | 83.0 (43.0–155.0) [n = 21] | 62.5 (47.8–105.8) [n = 20] | 56.0 (40.5– 73.0) [n = 7] | 69.0 (48.0– 75.0) [n = 7] | 53.0 (26.8– 77.8) [n = 6] | <0.01 [n = 18] | 0.07 [n = 4] |
| DHEAS (ng/dl) | 64.0 (51.0– 98.5) [n = 23] | 149.5 (104.0–196.8) [n = 22] | 135.0 (73.5–175.0) [n = 19] | 146.0 (46.0–188.0) [n = 17] | 84.0 (76.0–126.5) [n = 7] | 103.0 (81.2–151.8) [n = 4] | 124.0 (74.0–187.0) [n = 5] | 0.02 [n = 16] | 0.14 [n = 4] |
| Testosterone (ng/dl) | 12.0 (8.0–21.0) [n = 21] | 10.5 (8.8–15.2) [n = 16] | 11.0 (6.0–15.0) [n = 17] | 11.5 (6.2–17.2) [n = 14] | 8.5 (6.0–12.5) [n = 6] | 8.0 (3.5–12.2) [n = 4] | 5.0 (4.0–10.0) [n = 5] | 0.03 [n = 12] | 0.07 [n = 4] |
| DHEA: DHEAS ratio | 1.9 (1.2–2.5) [n = 23] | 0.7 (0.4–1.3) [n = 21] | 0.9 (0.5–1.0) [n = 19] | 0.7 (0.5–1.0) [n = 17] | 0.6 (0.3–1.0) [n = 7] | 0.7 (0.3–0.9) [n = 4] | 0.4 (0.3–0.9) [n = 5] | <0.01 [n = 16] | 0.07 [n = 4] |
DHEA dehydroepiandrosterone, DHEAS dehydroepiandrosterone sulphate
Data presented are median (inter quartile range)
a P value for Wilcoxon signed rank test comparing baseline and 3-month/6-month follow-up